Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies
Back to article page
OriginalPaper|Updated:2021-08-27
|
Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies
Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies
中国结合医学杂志(英文版)2012年18卷第3期 页码:209-213
Affiliations:
1. College of Pharmaceutical Science and Technology, Tianjin University,Tianjin,China
2. Tianjin Chase Sun Pharmaceutical Co., Ltd.,Tianjin,China
3. Tianjin Key Laboratory of Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Peking Union Medical College,Tianjin,China
Author bio:
Funds:
Supported by Tianjin Key Technology Research & Development Program (No. 07ZCKFSH00200)
Yao, Xq., Zhang, Yh., Long, W. et al. Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies., Chin. J. Integr. Med. 18, 209–213 (2012). https://doi.org/10.1007/s11655-012-1001-6
Xiao-qing Yao, Yun-hui Zhang, Wei Long, et al. Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies[J]. Chinese Journal of Integrative Medicine, 2012,18(3):209-213.
Yao, Xq., Zhang, Yh., Long, W. et al. Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies., Chin. J. Integr. Med. 18, 209–213 (2012). https://doi.org/10.1007/s11655-012-1001-6DOI:
Xiao-qing Yao, Yun-hui Zhang, Wei Long, et al. Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies[J]. Chinese Journal of Integrative Medicine, 2012,18(3):209-213. DOI: 10.1007/s11655-012-1001-6.
Oxysophoridine suppresses the growth of hepatocellular carcinoma in mice: In Vivo and cDNA microarray studies
摘要
To observe the in vivo effects of oxysophoridine on hepatocellular carcinoma in mice and to study the related mechanisms. C57BL mice were inoculated with mouse hepatoma H22 cells subcutaneously
then divided into 5 groups (14 per group)
and treated with oxysophoridine (50
100
or 150 mg/kg) or cisplatin (4 mg/kg) for 10 days. Inhibitory rate of tumor
body weight gain
and influence indices on internal organs (liver
spleen and thymus) were evaluated. The differentially expressed genes between the oxysophoridine-treated group
and the control group were analyzed using cDNA microarray and quantitative real-time PCR (qRT-PCR) experiments. Compared with the tumor weight of the control group (2.75±0.66 g)
oxysophoridine significantly suppressed hepatocellular carcinoma growth in mice (P <0.01)
with 0.82±0.36 g
0.57±0.22 g
and 1.22±0.67 g for the tumor weight in the low
moderate
and high dose treatment group
respectively. The moderate dose led to the highest inhibitory rate
79.3%. Observation of body weight gain and influence on three organs showed that compared with cisplatin
oxysophoridine produced fewer side effects in vivo. cDNA microarray and qRT-PCR showed that the most significant differentially expressed genes in the tumor samples of oxysophoridine-treated mice were mostly involved in regulating apoptosis
with the Tnfrsf11b (osteoprotegerin) gene being the most significantly affected. Oxysophoridine was a promising compound for developing drugs against hepatocellular carcinoma
and its anti-hepatoma effect was probably related to osteoprotegerin activation.
Abstract
To observe the in vivo effects of oxysophoridine on hepatocellular carcinoma in mice and to study the related mechanisms. C57BL mice were inoculated with mouse hepatoma H22 cells subcutaneously
then divided into 5 groups (14 per group)
and treated with oxysophoridine (50
100
or 150 mg/kg) or cisplatin (4 mg/kg) for 10 days. Inhibitory rate of tumor
body weight gain
and influence indices on internal organs (liver
spleen and thymus) were evaluated. The differentially expressed genes between the oxysophoridine-treated group
and the control group were analyzed using cDNA microarray and quantitative real-time PCR (qRT-PCR) experiments. Compared with the tumor weight of the control group (2.75±0.66 g)
oxysophoridine significantly suppressed hepatocellular carcinoma growth in mice (P <0.01)
with 0.82±0.36 g
0.57±0.22 g
and 1.22±0.67 g for the tumor weight in the low
moderate
and high dose treatment group
respectively. The moderate dose led to the highest inhibitory rate
79.3%. Observation of body weight gain and influence on three organs showed that compared with cisplatin
oxysophoridine produced fewer side effects in vivo. cDNA microarray and qRT-PCR showed that the most significant differentially expressed genes in the tumor samples of oxysophoridine-treated mice were mostly involved in regulating apoptosis
with the Tnfrsf11b (osteoprotegerin) gene being the most significantly affected. Oxysophoridine was a promising compound for developing drugs against hepatocellular carcinoma
and its anti-hepatoma effect was probably related to osteoprotegerin activation.
Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153–156.
Cherqui D. Role of adjuvant treatment in liver transplantation for advanced hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 1998;5:35–40.
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485–1491.
Tan A, Aucejo F, Kim R. Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma? Oncology 2010;78:161–171.
Atta-Ur-Rahman A, Choudhary MI, Parvez K, Ahmed A, Akhtar F, Nur EAM, Hassan NM. Quinolizidine alkaloids from Sophora alopecuroides. J Nat Prod 2000;63:190–192.
Sun J, Mao J, Liu X, Wang Y, Sun Y, He Z. Separation and mechanism elucidation for six structure-like matrinetype alkaloids by micellar liquid chromatography. J Sep Sci 2009;32:2043–2050.
Ding PL, Liao ZX, Huang H, Zhou P, Chen DF. (+)-12α-hydroxysophocarpine, a new quinolizidine alkaloid and related anti-HBV alkaloids from Sophora flavescens. Bioorg Med Chem Lett 2006;16:1231–1235.
Zhang HM, Li HQ. Anti-arrhythmic effects of sophoridine and oxysophoridine. Acta Pharmacol Sin 1999;20:517–520.
Huang X, Li B. Effects of six alkaloids of Sophora Alopecuroides on LTC4 and LTB4. Chin Tradit Patent Med (Chin) 2003;25:824–826.
Yu JQ, Jiang YX. Effects of oxysophoridine on Glu and GABA immuno-reaction positive neurons in cortex and hippocampus of rats. China J Chin Mater Med (Chin) 2006;31:1611–1614.
Yu J, Li Y, Zhao C, Gong X, Liu J, Wang F, Jiang Y. Effect of oxysophoridine on electric activities and its power spectrum of reticulum formation in rats. China J Chin Mater Med (Chin) 2010;35:1170–1172.
Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001;120:955–966.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402–408.
Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420–430.
Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 1998;273:5117–5123.
Lu TY, Kao CF, Lin CT, Huang DY, Chiu CY, Huang YS, Wu HC. DNA methylation and histone modification regulate silencing of OPG during tumor progression. J Cell Biochem 2009;108:315–325.
Bear bile powder (熊胆粉) induces apoptosis of human hepatocellular carcinoma cells via mitochondrion-dependent pathway
Preventive effects of Jiedu Granules (解毒颗粒) combined with Cinobufacini Injection (华蟾素注射液) versus transcatheter arterial chemoembolization in post-surgical patients with hepatocellular carcinoma: A case-control trial
Effects of Huogu I Formula (活骨I方) on correlated factors of bone regeneration in chickens with steroid-induced necrosis of femoral head
Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine
Total saponin from root of Actinidia Valvata Dunn prevents the metastasis of human hepatocellular carcinoma cells
相关作者
暂无数据
相关机构
Fujian Guizhentang Pharmaceutical Co., Ltd.
Fujian Key Laboratory of Integrative Medicine on Geriatrics, Fujian University of Traditional Chinese Medicine
Fujian Academy of Integrative Medicine
Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences